Lantern Pharma Inc. Q4 FY2023 earnings call

bullet-points:

• Computational and AI-driven approaches are key to Lantern's strategy in oncology drug discovery. 2023 was transformational with multiple clinical trials launched, peer-reviewed publications, RADR AI platform reaching over 60 billion data points and aiming for 100 billion, expansion of clinical infrastructure, and launch of Starlight Therapeutics focused on CNS cancers.
• Launched multiple clinical trials, including LP-184 in Phase I (over halfway enrolled) and LP-284 in Phase II. In-licensed and rescued LP-300 for never smokers with non-small cell lung cancer.
• Hired Dr. Marc Chamberlain for Starlight Therapeutics, preparing to launch initial adult trial in CNS cancers. Developed cryptophycin linked antibody drug conjugate in collaboration with German academic partners, showing high potency in picomolar range across solid tumors.
• RADR AI platform advanced with automation in data ingestion, curation, and algorithm generation, aiming to reach over 100 billion data points, and has modules for various drug development aspects.
• Strong cash position (~$41.3 million) to fuel growth, with 21 employees and 3 FTE consultants, expecting to expand in coming quarters.

There are no distinct product segments with revenue contribution percentages discussed. Financially, for the fourth quarter of 2023, general and administrative expenses were ~$1.3 million (down from ~$1.6 million prior year), R&D expenses were ~$3.6 million (up from ~$2.3 million prior year), and net loss was ~$4.2 million. For the full year 2023, R&D expenses were ~$11.9 million (up from ~$8.6 million in 2022), general and administrative expenses were ~$6.0 million (up slightly from $5.9 million in 2022), net loss was ~$15.96 million, and cash position was approximately $41.3 million as of December 31, 2023.

bullet-points:

• Advance and expand Phase I clinical trial for LP-184.
• Accelerate enrollment in LP-284 in non-Hodgkin's lymphomas and responsive cancers.
• Expand enrollment of Harmonic Trial into targeted sites in Asia where non-small cell lung cancer in never-smokers is higher.
• Explore licensing and partnership opportunities with biopharma companies.
• Expand RADR's platform to over 100 billion data points and develop additional collaborations.
• Progress Starlight Therapeutics towards Phase Ib/II adult and possibly Phase I pediatric clinical trials.
• Further ADC preclinical into IND development for future partnering or Phase I launch.
• Develop combination programs for existing drugs.
• Grow and mature clinical operations capabilities and maintain disciplined fiscal and financial management.

bullet-points:

• Factors causing actual results to differ from forward-looking statements, including results of clinical trials and impact of competition.
• Economic and political pressures on drug prices, which may affect the industry's approach to drug discovery and development.

Q: Business development opportunities?

A: Exploring three categories: deals with biotech companies using our platform, partnerships with big tech for RADR as a service, and traditional partnerships/licensing/selling assets to big pharma, with data driving these efforts.